<prof_article_slide_presentation>
    <front_label>Front Matter</front_label>
    <above_title>
        <p>
            <a href="/sites/advances/anticoagulation-thrombosis">Clinical Advances in Anticoagulation Management and Vascular Protection</a>
        </p>
    </above_title>
    <title>
        <p>Cancer‐Associated Thrombosis: Emerging Concepts and Paradigms</p>
    </title>
    <contrbtr_pre_content/>
    <contrbtr_byline>
        <p>Lord Ajay K. Kakkar, MD, PhD, FRCS, FRCP; Alok A. Khorana, MD; Jeffrey I. Weitz, MD, FRCP</p>
    </contrbtr_byline>
    <contrbtr_bulk_info/>
    <contrbtr_post_content>
        <h3>Peer Reviewer</h3>
        <p>This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships:
            <br/>Served as an advisor or consultant for: Abbott Laboratories; Medtronic, Inc.
        </p>
    </contrbtr_post_content>
    <supprtr_grant_group>
        <supprtr_grant_attr>/webmd/professional_assets/medscape/images/grant_attribution/daiichi-global-ieg-txt-2014.gif</supprtr_grant_attr>
    </supprtr_grant_group>
    <body_label>Body</body_label>
    <toc_element>
        <toc_label/>
        <toc_type>Default</toc_type>
        <sec_element>
            <sec_header>
                <p>Educational Impact Challenge</p>
            </sec_header>
            <subsec_element>
                <subsec_header/>
                <slide_intro>
                    <p>The goal of this activity is to provide an update on new treatment strategies for patients with cancer at risk for thromboembolism.</p>
                    <p>Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.</p>
                </slide_intro>
                <slide_grp>
                    <sec_img/>
                    <sec_label/>
                    <sec_caption/>
                    <sec_txt/>
                    <sec_alt_txt/>
                    <qna_form>3</qna_form>
                </slide_grp>
            </subsec_element>
        </sec_element>
        <pg_footnotes/>
    </toc_element>
    <toc_element>
        <toc_label/>
        <toc_type>Default</toc_type>
        <sec_element>
            <sec_header/>
            <subsec_element>
                <subsec_header/>
                <slide_intro>
                    <div class="app-loading">
                        <div class="webcomp-player" data-config="en/pi/editorial/studio/configs/2018/education/901602/901602.json" data-playertype="edu" id="cme-video-player">
                &#160;
            </div>
                    </div>
                    <div id="page_nav_top">
                        <div id="prev_page_nav">
                            <a href="901602">« Back </a>
                        </div>
                        <div id="next_page_nav">
                            <a href="901602_3">Next»</a>
                            <a href="javascript:next_toc();" id="next_toc_link" style="height: 17px;">
                                <img alt="" border="0" class="inline_img" src="http://img.medscape.com/pi/cme/ornaments/arrow-next-toc.png"/>
                            </a>
                        </div>
                        <div class="spacer">
                &#160;
            </div>
                    </div>
                </slide_intro>
                <slide_grp>
                    <sec_img>
                        <?dctmLink?>
                        <?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide1.png
                    </sec_img>
                    <sec_label>Slide 1.</sec_label>
                    <sec_caption/>
                    <sec_txt>
                        <h3> Cancer-Associated Thrombosis: Emerging Concepts and Paradigms</h3>
                    </sec_txt>
                    <sec_alt_txt>Slide 1.</sec_alt_txt>
                    <qna_form/>
                </slide_grp>
                <slide_grp>
                    <sec_img>
                        <?dctmLink?>
                        <?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide2.png
                    </sec_img>
                    <sec_label>Slide 2.</sec_label>
                    <sec_caption/>
                    <sec_txt>
                        <h3> Panelists</h3>
                    </sec_txt>
                    <sec_alt_txt>Slide 2.</sec_alt_txt>
                    <qna_form/>
                </slide_grp>
                <slide_grp>
                    <sec_img>
                        <?dctmLink?>
                        <?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide3.png
                    </sec_img>
                    <sec_label>Slide 3.</sec_label>
                    <sec_caption/>
                    <sec_txt>
                        <h3> Cancer-Associated Thrombosis: Who Is at Risk?</h3>
                        <ul>
                            <li>    Separating cancer into subcategories of patients who can or are likely to get blood clots vs those who are not likely to get blood clots is key</li>
                            <li> A single risk factor does not predict the full assessment of risk in this population </li>
                        </ul>
                    </sec_txt>
                    <sec_alt_txt>Slide 3.</sec_alt_txt>
                    <qna_form/>
                </slide_grp>
                <slide_grp>
                    <sec_img>
                        <?dctmLink?>
                        <?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide4.png
                    </sec_img>
                    <sec_label>Slide 4.</sec_label>
                    <sec_caption/>
                    <sec_txt>
                        <h3>Cancer-Associated Thrombosis: 
                            <em>How to Identify Those at Risk 
                                <sup type="ref">[1]</sup>
                            </em>
                        </h3>
                        <ul>
                            <li>     Surveys suggest that cancer patients are very unware of the risk of venous thromboembolism (VTE)</li>
                            <li>        They are very aware of becoming nauseated, having emesis, and getting infections and when to report these problems</li>
                            <li>     They are not aware of leg swelling or increased shortness of breath or sudden onset of chest pain as being concerning</li>
                            <li>   Providers must assess the risk, have a discussion, and educate patients about warning signs and symptoms of VTE </li>
                        </ul>
                    </sec_txt>
                    <sec_alt_txt>Slide 4.</sec_alt_txt>
                    <qna_form/>
                </slide_grp>
                <slide_grp>
                    <sec_img>
                        <?dctmLink?>
                        <?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide5.png
                    </sec_img>
                    <sec_label>Slide 5.</sec_label>
                    <sec_caption/>
                    <sec_txt>
                        <h3> Risk of VTE in Medical Patients
                            <sup type="ref">[2]</sup>
                        </h3>
                    </sec_txt>
                    <sec_alt_txt>Slide 5.</sec_alt_txt>
                    <qna_form/>
                </slide_grp>
                <slide_grp>
                    <sec_img>
                        <?dctmLink?>
                        <?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide6.png
                    </sec_img>
                    <sec_label>Slide 6.</sec_label>
                    <sec_caption/>
                    <sec_txt>
                        <h3>Primary Prevention Trials
                            <sup
type="ref">[3,4]</sup>
                        </h3>
                        <ul>
                            <li>     Two studies that will be completed soon are looking at prophylaxis with either rivaroxaban 10 mg once a day vs placebo or apixaban 2.5 mg twice a day vs placebo</li>
                            <li>        Both studies identify the highest risk patients </li>
                        </ul>
                    </sec_txt>
                    <sec_alt_txt>Slide 6.</sec_alt_txt>
                    <qna_form/>
                </slide_grp>
                <slide_grp>
                    <sec_img>
                        <?dctmLink?>
                        <?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide7.png
                    </sec_img>
                    <sec_label>Slide 7.</sec_label>
                    <sec_caption/>
                    <sec_txt>
                        <h3>Bleeding Risk in Patients With Cancer</h3>
                    </sec_txt>
                    <sec_alt_txt>Slide 7.</sec_alt_txt>
                    <qna_form/>
                </slide_grp>
                <slide_grp>
                    <sec_img>
                        <?dctmLink?>
                        <?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide8.png
                    </sec_img>
                    <sec_label>Slide 8.</sec_label>
                    <sec_caption/>
                    <sec_txt>
                        <h3>Treating the Patient With VTE
                            <sup type="ref">[1]</sup>
                        </h3>
                    </sec_txt>
                    <sec_alt_txt>Slide 8.</sec_alt_txt>
                    <qna_form/>
                </slide_grp>
                <slide_grp>
                    <sec_img>
                        <?dctmLink?>
                        <?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide9.png
                    </sec_img>
                    <sec_label>Slide 9.</sec_label>
                    <sec_caption/>
                    <sec_txt>
                        <h3>How Long to Treat?
                            <sup type="ref">[1]</sup>
                        </h3>
                    </sec_txt>
                    <sec_alt_txt>Slide 9.</sec_alt_txt>
                    <qna_form/>
                </slide_grp>
                <slide_grp>
                    <sec_img>
                        <?dctmLink?>
                        <?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide10.png
                    </sec_img>
                    <sec_label>Slide 10.</sec_label>
                    <sec_caption/>
                    <sec_txt>
                        <h3> NOACs vs LMWH In Patients With Cancer
                            <sup type="ref">[5,6]</sup>
                        </h3>
                    </sec_txt>
                    <sec_alt_txt>Slide 10.</sec_alt_txt>
                    <qna_form/>
                </slide_grp>
                <slide_grp>
                    <sec_img>
                        <?dctmLink?>
                        <?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide11.png
                    </sec_img>
                    <sec_label>Slide 11.</sec_label>
                    <sec_caption/>
                    <sec_txt>
                        <h3> Study Results
                            <sup type="ref">[5,6]</sup>
                        </h3>
                        <ul>
                            <li> In both those trials, the non-vitamin K antagonist oral anticoagulants (NOACs) were better in terms of reducing the risk of recurrent VTE with some increase in bleeding</li>
                            <li>        Both trials assessed the 6-month time point

                                <ul>
                                    <li>        The Hokusai study extended to 12 months, but for most patients the median time was around 6 months </li>
                                </ul>
                            </li>
                        </ul>
                    </sec_txt>
                    <sec_alt_txt>Slide 11.</sec_alt_txt>
                    <qna_form/>
                </slide_grp>
                <slide_grp>
                    <sec_img>
                        <?dctmLink?>
                        <?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide12.png
                    </sec_img>
                    <sec_label>Slide 12.</sec_label>
                    <sec_caption/>
                    <sec_txt>
                        <h3>LMWH
and VKAs
                            <sup type="ref">[7]</sup>
                        </h3>
                        <ul>
                            <li>  The advantage of low-molecular heparin vs vitamin K antagonist (VKA) is that you can titrate the dose </li>
                            <li> If, for example, a patient presents with
gastrointestinal bleeding (GI), a lower dose can be used to start and then the dose can be gradually increased when bleeding ceases</li>
                            <li>    Or, if a patient develops thrombocytopenia, you can titrate the dose down and ramp it back up again as the platelet count recovers</li>
                            <li>      There is a flexibility in dosing, which is not seen with VKAs

                                <ul>
                                    <li>        VKAs are only effective when the international normalized ratio (INR) is between 2 and 3, and that is difficult to maintain </li>
                                </ul>
                            </li>
                        </ul>
                    </sec_txt>
                    <sec_alt_txt>Slide 12.</sec_alt_txt>
                    <qna_form/>
                </slide_grp>
                <slide_grp>
                    <sec_img>
                        <?dctmLink?>
                        <?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide13.png
                    </sec_img>
                    <sec_label>Slide 13.</sec_label>
                    <sec_caption/>
                    <sec_txt>
                        <h3>Study Results (cont)
                            <sup type="ref">[5,6]</sup>
                        </h3>
                        <ul>
                            <li>        Hokusai VTE Cancer and SELECT-D studies had similar results</li>
                            <li>    Bleeding was seen especially in patients
with GI cancer </li>
                            <li>        There are now broader options for anticoagulation to manage thrombosis in our cancer patients </li>
                        </ul>
                    </sec_txt>
                    <sec_alt_txt>Slide 13.</sec_alt_txt>
                    <qna_form/>
                </slide_grp>
                <slide_grp>
                    <sec_img>
                        <?dctmLink?>
                        <?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide14.png
                    </sec_img>
                    <sec_label>Slide 14.</sec_label>
                    <sec_caption/>
                    <sec_txt>
                        <h3> Patient Persistence with Anticoagulant: 
                            <em>LMWH vs Oral Agents
                                <sup type="ref">[8]</sup>
                            </em>
                        </h3>
                        <ul>
                            <li> Consistently in studies looking at different populations -- older patients, younger patients, patients with private insurance, patients with Medicare -- the results are the same

                                <ul>
                                    <li>        Persistence on low molecular weight heparin (LMWH) is much lower than persistence on any oral agent, including VKAs</li>
                                </ul>
                            </li>
                            <li>  There is clearly a limitation of prolonged parenteral therapy that needs to be borne in mind</li>
                        </ul>
                    </sec_txt>
                    <sec_alt_txt>Slide 14.</sec_alt_txt>
                    <qna_form/>
                </slide_grp>
                <slide_grp>
                    <sec_img>
                        <?dctmLink?>
                        <?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide15.png
                    </sec_img>
                    <sec_label>Slide 15.</sec_label>
                    <sec_caption/>
                    <sec_txt>
                        <h3> Challenges of Anticoagulation Therapy</h3>
                        <ul>
                            <li>   In the Hokusai VTE Cancer study,
for example, only about 11% of the patients had hematological malignancies; thrombocytopenia was not a big issue</li>
                            <li>       In patents with lymphoma or leukemia, thrombocytopenia becomes a major challenge </li>
                            <li>       If anticoagulants are stopped, the risk of reoccurrence is at least around 20% in that first year
                                <sup type="ref">[9]</sup>
                            </li>
                        </ul>
                    </sec_txt>
                    <sec_alt_txt>Slide 15.</sec_alt_txt>
                    <qna_form/>
                </slide_grp>
                <slide_grp>
                    <sec_img>
                        <?dctmLink?>
                        <?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide16.png
                    </sec_img>
                    <sec_label>Slide 16.</sec_label>
                    <sec_caption/>
                    <sec_txt>
                        <h3> Ottawa Risk Score
                            <sup type="ref">[10]</sup>
                        </h3>
                        <ul>
                            <li>       The Ottawa score has not been validated in every study</li>
                            <li> It is very good at predicting low-risk patients, but not
so good at predicting high-risk patients </li>
                            <li>      The other challenge is all of these risk assessment tools were developed in the LMWH era</li>
                        </ul>
                    </sec_txt>
                    <sec_alt_txt>Slide 16.</sec_alt_txt>
                    <qna_form/>
                </slide_grp>
                <slide_grp>
                    <sec_img>
                        <?dctmLink?>
                        <?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide17.png
                    </sec_img>
                    <sec_label>Slide 17.</sec_label>
                    <sec_caption/>
                    <sec_txt>
                        <h3> Tailoring Treatment</h3>
                    </sec_txt>
                    <sec_alt_txt>Slide 17.</sec_alt_txt>
                    <qna_form/>
                </slide_grp>
                <slide_grp>
                    <sec_img>
                        <?dctmLink?>
                        <?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide18.png
                    </sec_img>
                    <sec_label>Slide 18.</sec_label>
                    <sec_caption/>
                    <sec_txt>
                        <h3> ISTH Guidance Statement
                            <sup type="ref">[11]</sup>
                        </h3>
                        <ul>
                            <li>     The term 
                                <em>suggest</em> has a specific meaning in the guidelines
                            </li>
                            <li>      The Hokusai VTE Cancer study carefully captured the different chemotherapeutic or biological agents being used by patients

                                <ul>
                                    <li>        A wide array of different agents was used, and there did not seem to be a problem with them </li>
                                </ul>
                            </li>
                        </ul>
                    </sec_txt>
                    <sec_alt_txt>Slide 18.</sec_alt_txt>
                    <qna_form/>
                </slide_grp>
                <slide_grp>
                    <sec_img>
                        <?dctmLink?>
                        <?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide19.png
                    </sec_img>
                    <sec_label>Slide 19.</sec_label>
                    <sec_caption/>
                    <sec_txt>
                        <h3>CARAVAGGIO
                            <sup type="ref">[12]</sup>
                        </h3>
                    </sec_txt>
                    <sec_alt_txt>Slide 19.</sec_alt_txt>
                    <qna_form/>
                </slide_grp>
                <slide_grp>
                    <sec_img>
                        <?dctmLink?>
                        <?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide20.png
                    </sec_img>
                    <sec_label>Slide 20.</sec_label>
                    <sec_caption/>
                    <sec_txt>
                        <h3> Managing Anticoagulation</h3>
                        <ul>
                            <li>        New International Society on Thrombosis and Haemostasis (ISTH) guidelines recommend taking patient preferences and values into account and having an informed discussion about the risk of bleeding and risk of recurrent VTE</li>
                        </ul>
                    </sec_txt>
                    <sec_alt_txt>Slide 20.</sec_alt_txt>
                    <qna_form/>
                </slide_grp>
                <slide_grp>
                    <sec_img>
                        <?dctmLink?>
                        <?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide21.png
                    </sec_img>
                    <sec_label>Slide 21.</sec_label>
                    <sec_caption/>
                    <sec_txt>
                        <h3> Managing Anticoagulation (cont)</h3>
                    </sec_txt>
                    <sec_alt_txt>Slide 21.</sec_alt_txt>
                    <qna_form/>
                </slide_grp>
                <slide_grp>
                    <sec_img>
                        <?dctmLink?>
                        <?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide22.png
                    </sec_img>
                    <sec_label>Slide 22.</sec_label>
                    <sec_caption/>
                    <sec_txt>
                        <h3> Summary </h3>
                    </sec_txt>
                    <sec_alt_txt>Slide 22.</sec_alt_txt>
                    <qna_form/>
                </slide_grp>
                <slide_grp>
                    <sec_img>
                        <?dctmLink?>
                        <?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide23.png
                    </sec_img>
                    <sec_label>Slide 23.</sec_label>
                    <sec_caption/>
                    <sec_txt>
                        <h3>Thank you</h3>
                    </sec_txt>
                    <sec_alt_txt>Slide 23.</sec_alt_txt>
                    <qna_form/>
                </slide_grp>
                <slide_grp>
                    <sec_img/>
                    <sec_label/>
                    <sec_caption/>
                    <sec_txt>
                        <em>This content has been condensed for improved clarity.</em>
                    </sec_txt>
                    <sec_alt_txt/>
                    <qna_form/>
                </slide_grp>
            </subsec_element>
            <subsec_element>
                <subsec_header>
                    <p>Educational Impact Challenge</p>
                </subsec_header>
                <slide_intro>
                    <p>What did you learn from this activity? Please click on the “Next” button to proceed to a brief survey to see how your knowledge improved after the education. You can also see how your answers compare with those of your peers.</p>
                </slide_intro>
            </subsec_element>
        </sec_element>
        <pg_footnotes/>
    </toc_element>
    <toc_element>
        <toc_label/>
        <toc_type>Default</toc_type>
        <sec_element>
            <sec_header>
                <p>Educational Impact Challenge</p>
            </sec_header>
            <subsec_element>
                <subsec_header/>
                <slide_intro/>
                <slide_grp>
                    <sec_img/>
                    <sec_label/>
                    <sec_caption/>
                    <sec_txt/>
                    <sec_alt_txt/>
                    <qna_form>4</qna_form>
                </slide_grp>
            </subsec_element>
        </sec_element>
        <pg_footnotes/>
    </toc_element>
    <toc_element>
        <toc_label/>
        <toc_type>Default</toc_type>
        <sec_element>
            <sec_header/>
            <subsec_element>
                <subsec_header/>
                <slide_intro/>
                <slide_grp>
                    <sec_img/>
                    <sec_label/>
                    <sec_caption/>
                    <sec_txt/>
                    <sec_alt_txt/>
                    <qna_form/>
                </slide_grp>
            </subsec_element>
        </sec_element>
        <pg_footnotes/>
    </toc_element>
    <toc_element>
        <toc_label>
            <p>Abbreviations</p>
        </toc_label>
        <toc_type>Sidebar</toc_type>
        <sec_element>
            <sec_header>
                <p>Abbreviations</p>
            </sec_header>
            <subsec_element>
                <subsec_header/>
                <slide_intro>
                    <p>CI = confidence interval
                        <br/>DVT = deep venous thrombosis
                        <br/>EGF = epidermal growth factor
                        <br/>GI = gastrointestinal
                        <br/>HR = hazard ratio
                        <br/>INR = international normalized ratio
                        <br/>ISTH = International Society on Thrombosis and Haemostasis
                        <br/>K-M = Kaplan-Meier
                        <br/>LMWH = low molecular weight heparin
                        <br/>NOAC = non-vitamin K antagonist oral anticoagulant
                        <br/>PE = pulmonary embolism
                        <br/>SC = subcutaneous
                        <br/>VEGF = vascular endothelial growth factor
                        <br/>VKA = vitamin K antagonist
                        <br/>VTE = venous thromboembolism
                    </p>
                </slide_intro>
            </subsec_element>
        </sec_element>
        <pg_footnotes/>
    </toc_element>
    <toc_element>
        <toc_label/>
        <toc_type>References</toc_type>
        <sec_element>
            <sec_header/>
            <subsec_element>
                <subsec_header/>
                <slide_intro>
                    <ol>
                        <li>Lyman GH, Bohlke K, Khorana AA, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. 
                            <em>J Clin Oncol</em>. 2015;33:654-656. 
                        </li>
                        <li>Cohen AT. Discoveries in thrombosis care for medical patients. 
                            <em>Semin Thromb Hemost</em>. 2002;28(suppl 3):13-17.
                        </li>
                        <li>ClinicalTrials.gov. Apixaban for the prevention of venous thromboembolism in cancer patients (AVERT). https://clinicaltrials.gov/ct2/show/NCT02048865. Accessed August 23, 2018.</li>
                        <li>Khorana AA, et al. Rivaroxaban for preventing venous thromboembolism in high-risk ambulatory patients with cancer: rationale and design of the CASSINI trial. 
                            <em>Thromb Haemost</em>. 2017;117:2135-2145. 
                        </li>
                        <li>Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. 
                            <em>N Engl J Med.</em> 2018;378:615-624.
                        </li>
                        <li>Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). 
                            <em>J Clin Oncol</em>. 2018;36:2017-2023. 
                        </li>
                        <li>Lee AY, Levine MN, Baker
RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. 
                            <em>N Engl J Med</em>. 2003;349:146-153.
                        </li>
                        <li>Khorana AA, McCrae KR, Milentijevic D, et al. Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis. 
                            <em>Res Pract Thromb Haemost</em>. 2017;1:14-22. 
                        </li>
                        <li>Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. 
                            <em>Blood</em>. 2002;100:3484-3488. 
                        </li>
                        <li>Louzada ML, Carrier M, Lazo-Langner A, et al. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer associated venous thromboembolism. 
                            <em>Circulation</em> 2012; 126: 448-454.
                        </li>
                        <li>Khorana AA, Noble S, Lee AYY, et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. 
                            <em>J Thromb Haemost</em>. 2018. [Epub ahead of print]
                        </li>
                        <li>Clinicaltrials.gov. Apixaban for the treatment of venous thromboembolism in patients with cancer (CARAVAGGIO)  https://clinicaltrials.gov/ct2/show/NCT03045406. Accessed August 23, 2018.</li>
                    </ol>
                </slide_intro>
            </subsec_element>
        </sec_element>
        <pg_footnotes/>
    </toc_element>
    <back_label>Back Matter</back_label>
    <ref_grp>
        <ref_item/>
    </ref_grp>
    <cpyrt_holder>
        <p>Medscape, LLC</p>
    </cpyrt_holder>
    <cpyrt_ovrd/>
    <disclmr_ovrd/>
    <bkmtr_front>
        <p>
            <strong>Disclaimer</strong>
        </p>
        <p>The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.</p>
        <p>The material presented here does not necessarily reflect the views of Medscape, LLC, or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.</p>
    </bkmtr_front>
    <bkmtr_glossary/>
    <bkmtr_ack/>
    <bkmtr_discl/>
    <bkmtr_funding/>
    <bkmtr_reprnt_addr/>
    <bkmtr_abbr_notes/>
    <bkmtr_last/>
    <img_ttl_bkgrd>/webmd/professional_assets/medscape/images/title_background/33543-collection-header.png</img_ttl_bkgrd>
    <img_publ_logo/>
</prof_article_slide_presentation>